GLP1R and digestive system disorder: Similarly, treatment with Semaglutide, an analogue of glucagon-like peptide-1 (GLP-1), has gastrointestinal disorders as the main adverse effects, and, despite being mild to moderate in severity, these complaints were the main causes related to the discontinuation of treatment [35,36].